Testing FPS-ZM1 for brain swelling after glioblastoma surgery
Original title: FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety and dose test in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug to see if it can help control brain swelling after glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary surgery.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary who have brain swelling after surgery. It tests a drug called FPS-ZM1, given with or without a steroid called dexamethasone.
Where it stands. This trial has not reported results. It is looking at how safe FPS-ZM1 is, what side effects it causes, and what the best dose is. The team also wants to see how well it controls brain swelling. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Nothing is proven here yet. If you have glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary and brain swelling after surgery is a concern, you could ask your care team about this study. They can tell you if it might fit your situation.
What it doesn't mean: This does not mean FPS-ZM1 works. A trial is a test, not a proven treatment. Joining a study is not a promise that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.